Physician profile
Tracy A Kramer
NPI 1548371438
$9,022.55
in general payments reported to CMS, 2019-2025
38 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $860 · 2023: $1,435 · 2024: $2,196 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,246.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,114.17 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $762.35 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $585.84 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $569.99 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Genzyme Corporation | $509.91 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $488.84 | 2024-2025 | Voquezna |
| Pfizer INC. | $450.72 | 2021-2025 | |
| Amgen INC. | $341.47 | 2023-2025 | Repatha, Evenity, Otezla |
| Astellas Pharma US INC | $284.55 | 2023-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $264.44 | 2022-2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $251.67 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $239.58 | 2021-2024 | Arexvy, Trelegy Ellipta, Bexsero |
| Sanofi-Aventis U.S. LLC | $226.08 | 2022-2025 | |
| Medtronic, INC. | $203.95 | 2021-2025 | Abre |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.